CN113855678A - Composition for adjuvant treatment of type II diabetes - Google Patents
Composition for adjuvant treatment of type II diabetes Download PDFInfo
- Publication number
- CN113855678A CN113855678A CN202111050493.6A CN202111050493A CN113855678A CN 113855678 A CN113855678 A CN 113855678A CN 202111050493 A CN202111050493 A CN 202111050493A CN 113855678 A CN113855678 A CN 113855678A
- Authority
- CN
- China
- Prior art keywords
- composition
- diabetes
- type
- parts
- adjuvant treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 19
- 238000009098 adjuvant therapy Methods 0.000 title claims abstract description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims abstract description 30
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 10
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 10
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 10
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 10
- 239000001168 astaxanthin Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims description 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000002000 scavenging effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a composition for adjuvant therapy of type II diabetes, which comprises the following raw materials, by weight, 1-9 parts of N-methylmorpholine and 0.1-2 parts of astaxanthin. The invention has the advantages that: scavenging free radicals in vivo, protecting islet cells, increasing insulin sensitivity, and inhibiting complications.
Description
Technical Field
The invention relates to the technical field of diabetes treatment, in particular to a composition for adjuvant therapy of type II diabetes.
Background
Currently, more and more diseases are attacking human health. Since the middle of the twentieth century, chronic diseases affecting human health, such as hypertension, diabetes, coronary heart disease, malignant tumor, etc., are mainly involved. In recent years, with the improvement of the dietary level of people, the incidence rate of chronic diseases is also increasing year by year, especially diabetes mellitus, which is more and more popular among people, from the top to the elderly, and from the bottom to children, is likely to become diabetic. The prevalence rate of diabetes mellitus in adults in China is 11.6%, and the prevalence rate of diabetes mellitus in men and women is 12.1% and 11.0% respectively, which are very common diseases difficult to cure radically.
Type II diabetes develops later in life, and it is often the organs and tissues that lose their ability to respond effectively to insulin. Type II diabetes has previously been referred to as non-insulin dependent diabetes mellitus or adult-onset diabetes. Type II diabetes accounts for approximately 90% to 95% of all diagnosed cases of diabetes as assessed by CDC. Risk factors for type II diabetes include higher age, obesity, family history of diabetes, history of gestational diabetes, impaired glucose tolerance, lack of exercise, and race/ethnicity, affecting a person's physical health.
Disclosure of Invention
The technical problem to be solved by the invention is to solve the problems and provide a composition for adjuvant therapy of type II diabetes.
In order to solve the technical problems, the technical scheme provided by the invention is as follows: a composition for adjuvant treatment of type II diabetes comprises, by weight, 1-9 parts of N-methylmorpholine and 0.1-2 parts of astaxanthin.
Further, the composition is one of a tablet, a powder, a granule or a capsule.
Further, the composition is one of an orally administered formulation, a food product, a beverage, or a nutraceutical.
After adopting the structure, the invention has the following advantages: the invention is based on the combination of the aspects of eliminating free radicals in vivo, protecting islet cells, increasing the sensitivity of insulin and inhibiting complications, and provides a health nutrient or medicament for preventing and controlling diabetes and high-risk people.
Drawings
FIG. 1 is a control panel of a composition of the present invention for use in the adjunctive treatment of type II diabetes.
FIG. 2 is a diagram of a panel of compositions of the present invention for use in the adjunctive treatment of type II diabetes.
FIG. 3 is a graph of a composition of the present invention for use in adjuvant treatment of type II diabetes mellitus after 8 weeks.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings.
With the combination of all the figures, the composition for adjuvant therapy of type II diabetes comprises the following raw materials, by weight, 1-9 parts of N-methylmorpholine and 0.1-2 parts of astaxanthin.
Further, the composition is one of a tablet, a powder, a granule or a capsule.
Further, the composition is one of an orally administered formulation, a food product, a beverage, or a nutraceutical.
In the specific implementation of the invention, 90 parts by weight of N-methylmorpholine and 10 parts by weight of astaxanthin are taken, and water is taken as an adhesive of a solvent to prepare wet granules; sieving the wet granules by a sieve of 10-40 meshes; drying the sieved granules at 20-80 ℃; and pressing and forming the dried granules by a tablet machine. The weight of each tablet was 300 mg.
20 female 8-week-old KM mice are selected, fed with high-fat and high-sugar feed for 30 days, and are subjected to intraperitoneal injection for 30mg/kg of body weight to measure STK for 2-4 days, and after confirming that the KM mice are obese, the KM mice are randomly divided into 2 groups.
Animals of each group were kept in an SPF (specific pathogen free) environment (room temperature 26 ℃ C., 12 hours day and night cycle) with free access to water. The experimental groups were gavaged daily for 12 weeks with the extract composition of the present invention.
Weighing animal body weight, fasting blood glucose (after fasting for 6h, cutting tail to draw blood, and measuring by rapid glucometer) glucose tolerance test (OGTT) (after fasting for 6h, feeding 2g/kg glucose for intragastric administration); data analysis was performed using T-test, p <0.05, as significant.
After 12 weeks of treatment, insulin tolerance experiments were performed. Fasting for 6h, and measuring tail vein blood sugar after injecting insulin (1U/kg) for 0min, 15min, 30min and 60 min.
When the composition of the invention is used for treating diabetic mice, as shown in figure 1, compared with a control group, the fasting blood glucose of an experimental group is obviously reduced. As shown in fig. 2, the insulin tolerance of the experimental group was significantly improved. Meanwhile, as shown in fig. 3, the body weight of mice in the experimental group was statistically different from that in the control group after 8 weeks of treatment with the composition of N-methylmorpholine (NMN) + astaxanthin (ASTA). The above results suggest that the composition of N-methylmorpholine (NMN) + astaxanthin (ASTA) has a certain therapeutic effect on diabetic mice.
The working principle of the invention is as follows: ingestion of high calorie foods destroys the anabolism of NAD +, and supplementation with N-methylmorpholine increases insulin sensitivity and ameliorates age-induced glucose intolerance. Astaxanthin has strong antioxidation effect, and can directly eliminate oxygen free radicals in cells. Protect the corresponding tissues from being damaged, recover the normal regulation function of the pancreatic islets, and can also inhibit the diabetic complications by removing the 'sugar virus' from the source.
The present invention and its embodiments have been described above, but the description is not limitative, and the actual structure is not limited thereto. In summary, those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiments as a basis for designing or modifying other structures for carrying out the same purposes of the present invention without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (3)
1. A composition for use in the adjunctive treatment of type ii diabetes mellitus, comprising: comprises the following raw materials of 1-9 parts by weight of N-methylmorpholine and 0.1-2 parts by weight of astaxanthin.
2. The composition for the adjuvant treatment of type ii diabetes according to claim 1, wherein: the composition is one of tablet, powder, granule or capsule.
3. The composition for the adjuvant treatment of type ii diabetes according to claim 1, wherein: the composition is one of an orally administered formulation, a food product, a beverage, or a nutraceutical.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111050493.6A CN113855678A (en) | 2021-09-08 | 2021-09-08 | Composition for adjuvant treatment of type II diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111050493.6A CN113855678A (en) | 2021-09-08 | 2021-09-08 | Composition for adjuvant treatment of type II diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113855678A true CN113855678A (en) | 2021-12-31 |
Family
ID=78994827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111050493.6A Pending CN113855678A (en) | 2021-09-08 | 2021-09-08 | Composition for adjuvant treatment of type II diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113855678A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1656178A (en) * | 2002-05-30 | 2005-08-17 | 化尔氏制药研究公司 | Oil-soluble pigment compositions |
| US20060241019A1 (en) * | 2003-07-25 | 2006-10-26 | Bridon Dominique P | Long lasting insulin derivatives and methods thereof |
| CN101313897A (en) * | 2008-06-27 | 2008-12-03 | 浙江工业大学 | Application of phaffia rhodozyma astaxanthin in preparing medicament for preventing and controlling type II diabetes |
| CN105106184A (en) * | 2015-09-25 | 2015-12-02 | 宁波大学 | Application of astaxanthin in preparation of medicine curing decreased insulin sensitivity |
| CN107048104A (en) * | 2017-06-06 | 2017-08-18 | 荆楚理工学院 | A kind of astaxanthin beverage for auxiliary treatment diabetes |
| CN112587575A (en) * | 2020-06-21 | 2021-04-02 | 吉林大学 | A pharmaceutical composition with antioxidant effect for treating diabetes |
-
2021
- 2021-09-08 CN CN202111050493.6A patent/CN113855678A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1656178A (en) * | 2002-05-30 | 2005-08-17 | 化尔氏制药研究公司 | Oil-soluble pigment compositions |
| US20060241019A1 (en) * | 2003-07-25 | 2006-10-26 | Bridon Dominique P | Long lasting insulin derivatives and methods thereof |
| CN101313897A (en) * | 2008-06-27 | 2008-12-03 | 浙江工业大学 | Application of phaffia rhodozyma astaxanthin in preparing medicament for preventing and controlling type II diabetes |
| CN105106184A (en) * | 2015-09-25 | 2015-12-02 | 宁波大学 | Application of astaxanthin in preparation of medicine curing decreased insulin sensitivity |
| CN107048104A (en) * | 2017-06-06 | 2017-08-18 | 荆楚理工学院 | A kind of astaxanthin beverage for auxiliary treatment diabetes |
| CN112587575A (en) * | 2020-06-21 | 2021-04-02 | 吉林大学 | A pharmaceutical composition with antioxidant effect for treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102273621B (en) | A kind of food of prevention and therapy diabetes or health food | |
| CN101590007A (en) | A kind of metformin hydrochloride/voigelibo sugar-lowering oral preparation compositions and preparation thereof | |
| CN106038704A (en) | Composition for inhibiting food digestion and absorption as well as preparation method and application of composition | |
| Hartajanie et al. | Probiotics fermented bitter melon juice as promising complementary agent for diabetes type 2: study on animal model | |
| JP6228250B2 (en) | Polysaccharide digestion inhibitor | |
| JP4657396B2 (en) | Amylase inhibitory active substance and use thereof | |
| CN112971154A (en) | Solid mixture rich in water-soluble dietary fibers and alpha-amylase inhibitor, and preparation method and application thereof | |
| CN113855678A (en) | Composition for adjuvant treatment of type II diabetes | |
| JP6257031B2 (en) | Prevention or treatment of urinary tract infections | |
| JP2004194635A (en) | Diet food | |
| CN110960502A (en) | Substance for treating metabolic syndrome and application thereof | |
| JP2011063557A (en) | Ppar activator | |
| CN101032545A (en) | Novel purpose of Chinese traditional medicine homonoia riparia | |
| CN101642477A (en) | Application of traditional Chinese medicine of pteris multifida | |
| CN101756993A (en) | Medical composition for losing weight or treating metabolic syndromes | |
| CN101347511B (en) | Medicament composition with function for reducing blood sugar | |
| CN109620858A (en) | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes | |
| CN109758448A (en) | Compound and its application for treating prediabetes and diabetes | |
| CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof | |
| CN106138025B (en) | Use of carnosic acid for treating type I diabetes | |
| CN104162163A (en) | Application of acyl-coenzyme A oxidase as therapeutic target of diabetes | |
| CN110193022B (en) | Application of chitosan oligosaccharide in improving lower limb ischemia caused by various diseases | |
| CN103316017A (en) | Bis(alpha-furancarboxylato)oxovanadium composition for treatment of diabetes | |
| CN108669530A (en) | A kind of Hericium erinaceus composition, tablet and preparation method conducive to stomach health | |
| KR102644056B1 (en) | Composition for preventing, improving or treating metabolic syndrome comprising β-gentiobiosyl paeoniflorinas as effective ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211231 |